Brentuximab Vedotin With Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (BV-CHEP) for the Treatment of Adult T-Cell Leukemia/Lymphoma: A Phase II Trial of the Rare Lymphoma Working Group
Phase of Trial: Phase II
Latest Information Update: 22 Nov 2019
Price : $35 *
At a glance
- Drugs Brentuximab vedotin (Primary) ; Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Etoposide (Primary) ; Prednisone (Primary)
- Indications Adult T-cell leukaemia-lymphoma
- Focus Therapeutic Use
- 12 Apr 2019 Status changed from active, no longer recruiting to recruiting.
- 02 Apr 2019 Status changed from recruiting to active, no longer recruiting.
- 31 Aug 2018 Biomarkers information updated